438 related articles for article (PubMed ID: 21073995)
21. Plasmodium falciparum malaria vaccines in development.
Vekemans J; Ballou WR
Expert Rev Vaccines; 2008 Mar; 7(2):223-40. PubMed ID: 18324891
[TBL] [Abstract][Full Text] [Related]
22. The development of malaria vaccines: SPf66--what next?
Tanner M; Alonso PL
Schweiz Med Wochenschr; 1996 Jul; 126(27-28):1210-5. PubMed ID: 8766632
[TBL] [Abstract][Full Text] [Related]
23. Pre-erythrocytic malaria vaccines: towards greater efficacy.
Hill AV
Nat Rev Immunol; 2006 Jan; 6(1):21-32. PubMed ID: 16493425
[TBL] [Abstract][Full Text] [Related]
24. Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A.
Walsh DS; Gettayacamin M; Leitner WW; Lyon JA; Stewart VA; Marit G; Pichyangkul S; Gosi P; Tongtawe P; Kester KE; Holland CA; Kolodny N; Cohen J; Voss G; Ballou WR; Heppner DG
Vaccine; 2006 May; 24(19):4167-78. PubMed ID: 16574282
[TBL] [Abstract][Full Text] [Related]
25. Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children.
Owusu-Agyei S; Ansong D; Asante K; Kwarteng Owusu S; Owusu R; Wireko Brobby NA; Dosoo D; Osei Akoto A; Osei-Kwakye K; Adjei EA; Boahen KO; Sylverken J; Adjei G; Sambian D; Apanga S; Kayan K; Vekemans J; Ofori-Anyinam O; Leach A; Lievens M; Demoitie MA; Dubois MC; Cohen J; Ballou WR; Savarese B; Chandramohan D; Gyapong JO; Milligan P; Antwi S; Agbenyega T; Greenwood B; Evans J
PLoS One; 2009 Oct; 4(10):e7302. PubMed ID: 19806184
[TBL] [Abstract][Full Text] [Related]
26. Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa.
Guerra Mendoza Y; Garric E; Leach A; Lievens M; Ofori-Anyinam O; Pirçon JY; Stegmann JU; Vandoolaeghe P; Otieno L; Otieno W; Owusu-Agyei S; Sacarlal J; Masoud NS; Sorgho H; Tanner M; Tinto H; Valea I; Mtoro AT; Njuguna P; Oneko M; Otieno GA; Otieno K; Gesase S; Hamel MJ; Hoffman I; Kaali S; Kamthunzi P; Kremsner P; Lanaspa M; Lell B; Lusingu J; Malabeja A; Aide P; Akoo P; Ansong D; Asante KP; Berkley JA; Adjei S; Agbenyega T; Agnandji ST; Schuerman L
Hum Vaccin Immunother; 2019; 15(10):2386-2398. PubMed ID: 31012786
[TBL] [Abstract][Full Text] [Related]
27. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial.
Aponte JJ; Aide P; Renom M; Mandomando I; Bassat Q; Sacarlal J; Manaca MN; Lafuente S; Barbosa A; Leach A; Lievens M; Vekemans J; Sigauque B; Dubois MC; Demoitié MA; Sillman M; Savarese B; McNeil JG; Macete E; Ballou WR; Cohen J; Alonso PL
Lancet; 2007 Nov; 370(9598):1543-51. PubMed ID: 17949807
[TBL] [Abstract][Full Text] [Related]
28. Malaria vaccines: are we getting closer?
Epstein JE; Giersing B; Mullen G; Moorthy V; Richie TL
Curr Opin Mol Ther; 2007 Feb; 9(1):12-24. PubMed ID: 17330398
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of phase 3 trial of RTS, S/AS01 malaria vaccine: The need for an alternative development plan.
Mahmoudi S; Keshavarz H
Hum Vaccin Immunother; 2017 Sep; 13(9):2098-2101. PubMed ID: 28272979
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of the introduction of a pre-erythrocytic malaria vaccine into the expanded program on immunization in sub-Saharan Africa: analysis of uncertainties using a stochastic individual-based simulation model of Plasmodium falciparum malaria.
Maire N; Shillcutt SD; Walker DG; Tediosi F; Smith TA
Value Health; 2011 Dec; 14(8):1028-38. PubMed ID: 22152171
[TBL] [Abstract][Full Text] [Related]
31. Malaria vaccine: a bright prospect for elimination of malaria.
Bairwa M; Rajput M; Khanna P; Rohilla R; Verma R; Chawla S
Hum Vaccin Immunother; 2012 Jun; 8(6):819-22. PubMed ID: 22739688
[TBL] [Abstract][Full Text] [Related]
32. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants.
; Agnandji ST; Lell B; Fernandes JF; Abossolo BP; Methogo BG; Kabwende AL; Adegnika AA; Mordmüller B; Issifou S; Kremsner PG; Sacarlal J; Aide P; Lanaspa M; Aponte JJ; Machevo S; Acacio S; Bulo H; Sigauque B; Macete E; Alonso P; Abdulla S; Salim N; Minja R; Mpina M; Ahmed S; Ali AM; Mtoro AT; Hamad AS; Mutani P; Tanner M; Tinto H; D'Alessandro U; Sorgho H; Valea I; Bihoun B; Guiraud I; Kaboré B; Sombié O; Guiguemdé RT; Ouédraogo JB; Hamel MJ; Kariuki S; Oneko M; Odero C; Otieno K; Awino N; McMorrow M; Muturi-Kioi V; Laserson KF; Slutsker L; Otieno W; Otieno L; Otsyula N; Gondi S; Otieno A; Owira V; Oguk E; Odongo G; Woods JB; Ogutu B; Njuguna P; Chilengi R; Akoo P; Kerubo C; Maingi C; Lang T; Olotu A; Bejon P; Marsh K; Mwambingu G; Owusu-Agyei S; Asante KP; Osei-Kwakye K; Boahen O; Dosoo D; Asante I; Adjei G; Kwara E; Chandramohan D; Greenwood B; Lusingu J; Gesase S; Malabeja A; Abdul O; Mahende C; Liheluka E; Malle L; Lemnge M; Theander TG; Drakeley C; Ansong D; Agbenyega T; Adjei S; Boateng HO; Rettig T; Bawa J; Sylverken J; Sambian D; Sarfo A; Agyekum A; Martinson F; Hoffman I; Mvalo T; Kamthunzi P; Nkomo R; Tembo T; Tegha G; Tsidya M; Kilembe J; Chawinga C; Ballou WR; Cohen J; Guerra Y; Jongert E; Lapierre D; Leach A; Lievens M; Ofori-Anyinam O; Olivier A; Vekemans J; Carter T; Kaslow D; Leboulleux D; Loucq C; Radford A; Savarese B; Schellenberg D; Sillman M; Vansadia P
N Engl J Med; 2012 Dec; 367(24):2284-95. PubMed ID: 23136909
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-blind bridging trial.
Macete EV; Sacarlal J; Aponte JJ; Leach A; Navia MM; Milman J; Guinovart C; Mandomando I; López-Púa Y; Lievens M; Owusu-Ofori A; Dubois MC; Cahill CP; Koutsoukos M; Sillman M; Thompson R; Dubovsky F; Ballou WR; Cohen J; Alonso PL
Trials; 2007 Mar; 8():11. PubMed ID: 17386091
[TBL] [Abstract][Full Text] [Related]
34. Malaria vaccine: a current perspective.
Sharma S; Pathak S
J Vector Borne Dis; 2008 Mar; 45(1):1-20. PubMed ID: 18399312
[TBL] [Abstract][Full Text] [Related]
35. Characterization of T-cell immune responses in clinical trials of the candidate RTS,S malaria vaccine.
Moris P; Jongert E; van der Most RG
Hum Vaccin Immunother; 2018 Jan; 14(1):17-27. PubMed ID: 28934066
[TBL] [Abstract][Full Text] [Related]
36. Malaria vaccine.
Khurana SK; Talib VH
Indian J Pathol Microbiol; 1996 Dec; 39(5):433-41. PubMed ID: 9002371
[TBL] [Abstract][Full Text] [Related]
37. The public health impact of malaria vaccine RTS,S in malaria endemic Africa: country-specific predictions using 18 month follow-up Phase III data and simulation models.
Penny MA; Galactionova K; Tarantino M; Tanner M; Smith TA
BMC Med; 2015 Jul; 13():170. PubMed ID: 26219380
[TBL] [Abstract][Full Text] [Related]
38. The RTS,S vaccine candidate for malaria.
Regules JA; Cummings JF; Ockenhouse CF
Expert Rev Vaccines; 2011 May; 10(5):589-99. PubMed ID: 21604980
[TBL] [Abstract][Full Text] [Related]
39. Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific.
Alloueche A; Milligan P; Conway DJ; Pinder M; Bojang K; Doherty T; Tornieporth N; Cohen J; Greenwood BM
Am J Trop Med Hyg; 2003 Jan; 68(1):97-101. PubMed ID: 12556156
[TBL] [Abstract][Full Text] [Related]
40. RTS,S: Toward a first landmark on the Malaria Vaccine Technology Roadmap.
Kaslow DC; Biernaux S
Vaccine; 2015 Dec; 33(52):7425-32. PubMed ID: 26431982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
